“Due to the Company’s strong financial backing from our $10 million equity line from Aspire Capital, and further progress in our clinical trials, we are intending to move to a senior exchange,” commented Leo Ehrlich, CEO.


I take it the further progress in our clinical trials is somewhere between good and out-of-this-world fantastic.  Anything less would make an intention to up-list unfounded.  Sounds good to me!